Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Clinical effectiveness of a combination of metformin and ipragliflozin in the management of patients with type-2 diabetes mellitus

Xiaojie Tan¹, Guijuan Sun², Fei Yuan³, Linfang Qu³, Aiqiang Han⁴

¹Department of Pharmacy, Jiaozhou Central Hospital of Qingdao; ²Department of Encephalopathy; ³Department of Internal Medicine, Shandong Qingdao Integrated Traditional Chinese and Western Medicine Hospital, Shandong; ⁴Department of Health, The Second People's Hospital of Weifang, Weifang, China.

For correspondence:- Aiqiang Han Email: qianghuiaoaohkx@163.com

Accepted: 3 April 2021 Published: 30 April 2021

Citation: Tan X, Sun G, Yuan F, Qu L, Han A. Clinical effectiveness of a combination of metformin and ipragliflozin in the management of patients with type-2 diabetes mellitus. Trop J Pharm Res 2021; 20(4):783-788 doi: 10.4314/tjpr.v20i4.18

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the clinical effectiveness of combination of metformin and ipragliflozin in the treatment of patients with type-2 diabetes mellitus (T2DM).

Methods: Patients with T2DM (n = 100) aged 35 – 68 years (mean age = 51.5 ± 16.5 years) were recruited over a 1-year period and randomly assigned to 2 groups (50 patients/group): control and study groups. Control group patients were treated with metformin orally at a dose of 500 mg/kg body weight twice a day, while patients in the study group received 50 mg ipragliflozin/kg, orally once a day, in addition to metformin. Fasting blood glucose (FBG), 2-h postprandial blood glucose (PBG), bedtime glucose (BBG) and glycated hemoglobin (HbAlc) concentrations were measured in patients’ plasma before and after treatment. Incidence of adverse reactions, changes in body fat and clinical effectiveness were also determined.

Results: FBG, 2-h PBG, BBG, HbAlc, body fat and incidence of adverse reactions were markedly reduced in T2DM patients treated with the combination of metformin and ipragliflozin, relative to those treated with metformin alone (p < 0.05). After treatment, the proportion of outcomes categorized as ‘markedly effective’ and ‘total effectiveness’ was higher in the study group than in the control group (p < 0.05).

Conclusion: The combination of metformin and ipragliflozin is safer and more clinically effective in the treatment of T2DM than metformin monotherapy.

Keywords: Blood glucose, Diabetes mellitus, Clinical effectiveness, Ipragliflozin, Metformin